Polycystic ovary syndrome and risk for long-term diabetes and dyslipidemia
- PMID: 21173640
- PMCID: PMC3060760
- DOI: 10.1097/AOG.0b013e31820209bb
Polycystic ovary syndrome and risk for long-term diabetes and dyslipidemia
Abstract
Objective: To estimate whether women aged 20-32 years who fulfilled National Institutes of Health criteria for polycystic ovary syndrome (PCOS) would be at higher risk for subsequent development of incident diabetes, dyslipidemia, and hypertension, and to estimate whether normal-weight women with PCOS would have the same degree of cardiovascular risk as overweight women with PCOS.
Methods: We estimated the association of PCOS with incident diabetes, dyslipidemia, and hypertension over a period of 18 years among 1,127 white and African-American women in the Coronary Artery Risk Development in Young Adults cohort. We classified women at baseline (ages 20-32 years) based on self-reported symptoms and serum androgen measures using National Institutes of Health PCOS criteria. We estimated the association of PCOS and subsequent cardiovascular risk factors, independent of baseline body mass index (BMI), using multivariable logistic regression. Additionally, among 746 women with a second assessment of PCOS at ages 34-46 years, we estimated the association of persistent PCOS with cardiovascular risk factors.
Results: Of 1,127 women, 53 (4.7%) met criteria for PCOS at ages 20-32 years. Polycystic ovary syndrome was associated with a twofold higher odds of incident diabetes (23.1% compared with 13.1%, adjusted odds ratio [AOR] 2.4, confidence interval [CI] 1.2-4.9) and dyslipidemia (41.9% compared with 27.7%, AOR 1.9, CI 1.0-3.6) over the course of 18 years; the association with incident hypertension was not significant (26.9% compared with 26.3%, AOR 1.7, CI 0.8-3.3). Normal-weight women with PCOS (n=31) had a threefold higher odds of incident diabetes compared with normal-weight women without PCOS (AOR 3.1, CI 1.2-8.0). Compared with those without PCOS, women with persistent PCOS (n=11) had the highest odds of diabetes (AOR 7.2, CI 1.1-46.5).
Conclusion: Polycystic ovary syndrome is associated with subsequent incident diabetes and dyslipidemia, independent of BMI. Diabetes risk may be greatest for women with persistent PCOS symptoms.
Level of evidence: II.
Conflict of interest statement
Comment in
-
Defining risk in women with polycystic ovary syndrome: a need for constant vigilance.Obstet Gynecol. 2011 Jan;117(1):1-2. doi: 10.1097/AOG.0b013e318202f06c. Obstet Gynecol. 2011. PMID: 21173638 No abstract available.
Similar articles
-
Epidemiology and comorbidities of polycystic ovary syndrome in an indigent population.J Investig Med. 2014 Aug;62(6):868-74. doi: 10.1097/01.JIM.0000446834.90599.5d. J Investig Med. 2014. PMID: 24844662
-
Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome.J Clin Endocrinol Metab. 2006 Apr;91(4):1357-63. doi: 10.1210/jc.2005-2430. Epub 2006 Jan 24. J Clin Endocrinol Metab. 2006. PMID: 16434451
-
Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome.Cardiovasc Diabetol. 2018 Mar 8;17(1):37. doi: 10.1186/s12933-018-0680-5. Cardiovasc Diabetol. 2018. PMID: 29519249 Free PMC article.
-
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME - PART 2.Endocr Pract. 2015 Dec;21(12):1415-26. doi: 10.4158/EP15748.DSCPT2. Endocr Pract. 2015. PMID: 26642102 Review.
-
Cardiovascular disease risk factors in polycystic ovary syndrome.Semin Reprod Med. 2008 Jan;26(1):39-44. doi: 10.1055/s-2007-992923. Semin Reprod Med. 2008. PMID: 18181081 Review.
Cited by
-
Metabolic profiles characterizing different phenotypes of polycystic ovary syndrome: plasma metabolomics analysis.BMC Med. 2012 Nov 30;10:153. doi: 10.1186/1741-7015-10-153. BMC Med. 2012. PMID: 23198915 Free PMC article. Clinical Trial.
-
Female-specific factors for IHD: across the reproductive lifespan.Curr Atheroscler Rep. 2015;17(2):481. doi: 10.1007/s11883-014-0481-6. Curr Atheroscler Rep. 2015. PMID: 25620277 Review.
-
Women's Reproductive Milestones and Cardiovascular Disease Risk: A Review of Reports and Opportunities From the CARDIA Study.J Am Heart Assoc. 2023 Mar 7;12(5):e028132. doi: 10.1161/JAHA.122.028132. Epub 2023 Feb 27. J Am Heart Assoc. 2023. PMID: 36847077 Free PMC article. Review.
-
Genetics and Epigenetics of Infertility and Treatments on Outcomes.J Clin Endocrinol Metab. 2019 Jun 1;104(6):1871-1886. doi: 10.1210/jc.2018-01869. J Clin Endocrinol Metab. 2019. PMID: 30561694 Free PMC article. Review.
-
Association of severity of menstrual dysfunction with hyperinsulinemia and dysglycemia in polycystic ovary syndrome.Hum Reprod. 2022 Mar 1;37(3):553-564. doi: 10.1093/humrep/deac001. Hum Reprod. 2022. PMID: 35048126 Free PMC article.
References
-
- Zawadski J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach. In: Dunaif A, Givens J, Haseltine F, Merriam G, editors. Polycystic Ovary Syndrome. Boston: Blackwell Scientific Publications; 1992. pp. 377–384.
-
- Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999 Jan;84(1):165–169. - PubMed
-
- Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med. 2001 Dec 1;111(8):607–613. - PubMed
-
- Lo JC, Feigenbaum SL, Yang J, Pressman AR, Selby JV, Go AS. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab. 2006 Apr;91(4):1357–1363. - PubMed
-
- Taponen S, Martikainen H, Jarvelin MR, Sovio U, Laitinen J, Pouta A, et al. Metabolic cardiovascular disease risk factors in women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland Birth Cohort 1966 Study. J Clin Endocrinol Metab. 2004 May;89(5):2114–2118. - PubMed
Publication types
MeSH terms
Grants and funding
- N01 HC048048/HC/NHLBI NIH HHS/United States
- N01-HC-48047/HC/NHLBI NIH HHS/United States
- R01-HL-065611/HL/NHLBI NIH HHS/United States
- N-01-HC-48049/HC/NHLBI NIH HHS/United States
- N01-HC-95095/HC/NHLBI NIH HHS/United States
- N01 HC048049/HC/NHLBI NIH HHS/United States
- N01 HC048047/HL/NHLBI NIH HHS/United States
- R01 HL065622/HL/NHLBI NIH HHS/United States
- N01 HC048050/HL/NHLBI NIH HHS/United States
- N01-HC-48048/HC/NHLBI NIH HHS/United States
- N01 HC045204/HL/NHLBI NIH HHS/United States
- N01 HC095095/HL/NHLBI NIH HHS/United States
- N01-HC-45205/HC/NHLBI NIH HHS/United States
- N01-HC-05187/HC/NHLBI NIH HHS/United States
- N01 HC048050/HC/NHLBI NIH HHS/United States
- N01 HC048048/HL/NHLBI NIH HHS/United States
- N01 HC048047/HC/NHLBI NIH HHS/United States
- N01-HC-45204/HC/NHLBI NIH HHS/United States
- N01 HC048049/HL/NHLBI NIH HHS/United States
- R01 HL065611/HL/NHLBI NIH HHS/United States
- N01 HC045205/HC/NHLBI NIH HHS/United States
- N01-HC-48050/HC/NHLBI NIH HHS/United States
- N01 HC095095/HC/NHLBI NIH HHS/United States
- N01 HC045205/HL/NHLBI NIH HHS/United States
- N01 HC045204/HC/NHLBI NIH HHS/United States
- N01 HC005187/HC/NHLBI NIH HHS/United States
- N01 HC005187/HL/NHLBI NIH HHS/United States
- N01 HC045134/HC/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous